ILSI-Biomed Israel

BioMed 2010 week Innovations: The New Generation of PainShield

NanoVibronix will present the second generation of PainShield – for the treatment of pain and chronic wounds using ultrasound waves Following the commercial success of the first generation PainShield device, for the treatment of (surprise, surprise) pain, especially one that stems from Trigeminal Neualgia, the Israeli company NanoVibronix now reveals the second generation of the device. This time, it has some extra capabilities to treat chronic wounds. NanoVibronix, based in Nesher, is develo...

Israel’s Life Sciences Export On the Rise

The Coming ILSI–Biomed Israel 2010 Week: The Israel Export and International Cooperation Institute: Life Sciences Export Rose by 14% on the First Quarter of 2010, Summing up to the Total of ca. $1.7 Billion “The first 2010 quarter export of the life sciences industry summed up to ca. $1.7 billion, an increase of about 14 percent compared to the same period last year. This increase is derived from a 15.4 percent increase in the export of medications, which has summed up to ca. $1.3 Billion...

Stem Cells as Seek-and-Destory Missiles against Cancer

As published in New Scientist, stem cells were succesfully modified to act as seek-and-destroy missiles against cancer in mice brains Stem cells are often viewed as the ultimate solution for regenerative medicine, and for a good cause. Given the correct cues, they can regenerate whole parts of the body, and even re-create an entire embryo (although that would require QUITE some understanding of the cues involved in the process). It seems, however, that now a new use has been found for the...

Biotech co D Medical files for Nasdaq listing

Biotech co D Medical files for Nasdaq listing: If the offering is successful, it will greatly dilute the holdings of its current shareholders.  The management of medical device holding company D Medical Industries Ltd. (TASE:DMDC) are not deterred by the falls on the Tel Aviv Stock Exchange (TASE) and on Wall Street over the past few weeks. The company today announced that it has filed a draft prospectus with the US Securities and Exchange Commission (SEC) for a public offering and reques...

A Novel Israeli Kit for Regaining Feeling in the Palms

Sheba Hospital will expose a Israeli kit for sensory training, that improves the brain activity for patients who suffer from a decrease in feeling in the palms The Department for Multiple Sclerosis in Sheba Hopsital will present for the first time a novel kit for sensory training, that improves patients' brain activity. The kit will be presented in the BioMed Israel Week 2010, which will be held on July 14th-16th in Tel Aviv. The kit is based on cylinders that come in varied textures, an...

Researchers from RAMBAM Hospital Fight Parkinson’s Disease with Imagination

A new research from RAMBAM hospital shows that Guided Affective Imagery (דמיון מודרך) can make the tremors of Parkinson's disease go away. The relationship between the mind and the body has never been fully determined. Worse, the field is wide open for charlatans, holistic healers, homeopaths, naturopaths and what-have-you. However, from time to time we get some ‘real’ peer-reviewed scientific papers that offer new insights on the mind-body link. Such a paper was recently published in the...

Human Beta Cells Grown in a Culture

From BioMed Israel Week 2010: A Novel Therapeutic Method Based on the Ability of Stem Cells to Assist in Treating Juvenile Diabetes Will Replace the Insulin Injection Ramot, Tel Aviv University's technology transfer company, will present for the first time a therapeutic approach based on stem cells capability to assist in the treatment of juvenile diabetes, in the Israel BioMed Week 2010, which will be held on the 14th-16th of June in Tel Aviv. The main novelty of the treatment is a br...

Startup Weekly: ProtAb – Antibodies Against Arthritis

ProtAb is a company dedicated to eveloping an antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn's Disease, and has recently raised $4 million. Name: ProtAb CEO: Shira Yair Sector: Biopharma Medical Field: Autoimmune Diseases Est.: 2005 Stage: Late stage pre-clinical, after series A funding Vision: To develop a novel therapeutics for autoimmune diseases, based on the induction of natural anti-inflammatory mechanisms existing in...

A Novel Artificial Pancreas System

An aritifical pancreas system that maintains near-normal glucose levels by injecting both insulin and glucagon was succesfully demonstrated on a small number of patients An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin an...

Enzymotec: a $20 M Deal with Daiichi Sankyo

Israeli biotech company Enzymotec Ltd., a developer of active pharmaceutical ingredients for nutritional supplements, has signed a major strategic agreement with Daiichi Sankyo Brazil, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo Co. Ltd. (TSE: 4568). Globes, 6 May Enzymotec and Daiichi Sankyo Brazil will launch Enzymotec's product for the reduction of cholesterol and triglycerides, which Daiichi Sankyo Brazil will market. Daiichi Sankyo Brazil focuses on cardiology a...